When biologics should be used in systemic lupus erythematosus?

Jacques‐Eric Gottenberg(Centre National de la Recherche Scientifique), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Arnaud Theulin(Hôpitaux Universitaires de Strasbourg), Christelle Sordet, Noël Lorenzo(Hôpitaux Universitaires de Strasbourg), Emmanuel Chatelus(Laboratoire National de Référence)
La Presse Médicale
June 1, 2014
10.1016/j.lpm.2014.04.006
Cited by 5

Related Papers

<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
|Blood|1997|346
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207